Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.

doi:10.1038/s41467-025-68076-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.

Nature communications - 3 Jan 2026

Rose April A N, Maxwell Jennifer, Rousselle Emmanuelle, Mukonoweshuro Chantel L, Elkholi Islam E, Riaud Melody, Biondini Marco, Cianfarano Erica, Soria-Bretones Isabel, Tobin Chantal, McGuire Meghan, Law Rhoda W Y, Elia Andrew J, Wang Ben X, King Ian, Zhang Tong, Pugh Trevor J, Kamil Zaid Saeed, Butler Marcus, Shepherd Frances A, Leighl Natasha B, Razak Albiruni Abdul, Hansen Aaron, Saibil Samuel D, Bedard Philippe L, Siegel Peter M, Siu Lillian L, Cescon David W, Spreafico Anna

Abstract excerpt

Class 2 and 3 non-V600E BRAF mutations are oncogenic drivers in many cancer types. Currently, there are no established targeted therapies with proven efficacy for cancers with non-V600E BRAF mutations. We developed the investigator-initiated, Phase II BEAVER clinical trial (NCT03839342) to evaluate the efficacy of BRAF and MEK inhibitors in patients with non-V600E BRAF mutations. The primary outcome was objective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Carbamates

Share to Circulating Tumor DNA

Share to MAP Kinase Kinase 1

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41484121
DOI: 10.1038/s41467-025-68076-7
PMCID: PMC12873207

Genes

BRAF
CDK4
MAP2K1
NRAS
RAF1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.PMID 41484121Read ↗

CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancersSemantic proximity Read ↗

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesSemantic proximity Read ↗

Defining and Targeting BRAF Mutations in Solid Tumors.Semantic proximity Read ↗

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistanceSemantic proximity Read ↗

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design.Semantic proximity Read ↗

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.Semantic proximity Read ↗

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.Semantic proximity Read ↗

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumorsSemantic proximity Read ↗

A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumorsSemantic proximity Read ↗

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.Semantic proximity Read ↗

Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.